87639-57-4

Usage

Uses

Used in Pharmaceutical Industry:
DIMETHYL 4-BROMOPHTHALATE is used as an intermediate in the synthesis of various pharmaceuticals for its ability to facilitate the production of complex organic molecules that are integral to the development of new drugs.
Used in Agrochemical Industry:
In the agrochemical sector, DIMETHYL 4-BROMOPHTHALATE is utilized as an intermediate in the production of agrochemicals, contributing to the development of compounds that aid in crop protection and enhancement of agricultural yields.
Used in Dye Industry:
DIMETHYL 4-BROMOPHTHALATE is employed as an intermediate in the synthesis of dyes, playing a crucial role in the creation of colorants used in various industries, including textiles, plastics, and printing.
Used as a Reagent in Organic Chemical Reactions:
DIMETHYL 4-BROMOPHTHALATE is used as a reagent in esterification and acylation processes, enabling the formation of esters and amides, which are essential in the synthesis of a wide range of organic compounds.

InChI:InChI=1/C10H9BrO4/c1-14-9(12)7-4-3-6(11)5-8(7)10(13)15-2/h3-5H,1-2H3

Upstream product

• 86-90-8 4-bromophthalic anhydride 
• 67-56-1 methanol 
• 6968-28-1 4-bromophthalic acid 

Downstream Products

• 22803-05-0 4,4'-biphthalic acid 
• 2420-87-3 3,3',4,4'-biphenyltetracarboxylic anhydride 
• 939053-19-7 dimethyl 4-(2-(9-(diethylamino)-5-oxo-5H-benzo[a]phenoxazin-2-yl)ethynyl)benzene-1,2-dicarboxylate 
• 171011-37-3 4-bromo-2-(hydroxymethyl)benzyl alcohol 
• 22895-19-8 dimethyl 4-methoxyphtalate 
• 36978-37-7 3,3',4,4'-biphenyltetracarboxylic acid tetramethyl ester 
• 36978-36-6 2,3,3',4'-biphenyltetracarboxylic acid tetramethyl ester 
• 131-11-3 phthalic acid dimethyl ester 

Relevant academic research and scientific papers

TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE

This disclosure relates to bivalent compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the bivalent compounds, and to methods of use the bivalent compounds for the treatment of certain disease in a subject in need thereof. The disclosure also relates to methods for identifying such bivalent compounds.

TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE

The present disclosure relates to bifunctional compounds, which find utility as modulators of tan protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tan protein, such that tan protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tan. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tan protein. Diseases or disorders that result from aggregation or accumulation of tan protein are treated or prevented with compounds and compositions of the present disclosure.

Highly selective electroreductive linear dimerization of electron-deficient vinylarenes

A direct electroreductive dimerization of electron-deficient vinylarenes for the synthesis of 1,4-diarylbutane has been developed using a simple undivided cell with inexpensive carbon electrodes at room temperature. The control and deuterium-labeling experiments of electroreductive dimerization suggest that the hydrogen source comes from the solvent CH3CN. This protocol provides a mild and efficient route for the construction of C–C bond in moderate to good yields with high regioselectivity and broad substrate scope.

TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE

Bivalent compounds, compositions comprising one or more of the bivalent compounds, and methods of use the bivalent compounds for the treatment of certain disease in a subject in need thereof are provided. Methods for identifying such bivalent compounds are provided, either.

PFKFB3 INHIBITORS AND THEIR USES

This disclosure relates to new phthalimide and isoindolinone derivatives and other PFKFB3 inhibitors for use in the treatment of diseases. The invention further relates to pharmaceutical compositions containing such PFKFB3 inhibitors, methods of preparation thereof, methods for their use as therapeutic agents, and methods of preparation of a medicament for use in therapy, as well as kits and other inventiions comprising such PFKFB3 inhibitors. These PFKFB3 inhibitors are useful for the treatment and prophylaxis of cancer, neurodegenerative diseases, autoimmune diseases, inflammatory disorders, multiple sclerosis, metabolic diseases, inhibition of angiogenesis and other diseases and conditions, where the modulation of PFKFB3 and/or PFKFB4 has beneficial effect as well as neuroprotection.

Preparation method of room-temperature phosphorescent benzoate compound

The invention relates to a room-temperature phosphorescent benzoate compound. The benzoate compound is prepared by an efficient one-step method, and the prepared benzoate compound has obvious phosphorescence at room temperature, thereby broadening the application range of the benzoate compound. The product can be widely applied to phosphorescent materials.

Chiral Supramolecular U-Shaped Catalysts Induce the Multiselective Diels-Alder Reaction of Propargyl Aldehyde

The Diels-Alder reaction, which is a traditional [4 + 2] cycloaddition with two carbon-carbon bond formations, is one of the most powerful tools to synthesize versatile and unique six-membered rings. We show that chiral supramolecular U-shaped boron Lewis acid catalysts promote the unprecedented multiselective Diels-Alder reaction of propargyl aldehyde with cyclic dienes. Independent from the substrate control, enantio-, endo/exo-, π-facial-, regio-, site-, and substrate-selectivities could be controlled by the present U-shaped catalysts. The obtained reaction products could access the concise synthesis of chiral diene ligands and a key intermediate of (+)-sarkomycin. The results presented here might partially contribute to the development of artificial enzyme-like supramolecular catalysts for multiselective reactions, which will be able to target organic compounds that have thus far eluded synthesis.

Restricted 9-cis retinoids

The invention is novel analogs of 9-cis-retinoic acid which are useful for the treatment and prevention of coronary artery disease and to protect against premature atherosclerosis by increasing HDL levels. The invention includes processes for preparing th